June 29, 2022
1 min watch
Save
VIDEO: DETERMINATION study ‘eagerly awaited’ by transplant community
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses the phase 3 DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Krishnan notes that while the arrival of phase 3 results from DETERMINATION was a major development in the multiple myeloma field, she did not think it produced definitive answers, although it showed potential benefit to stem cell transplantation.
“It did meet its primary endpoint of progression-free survival,” Krishnan said.
Reference:
- Richardson P, et al. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Krishnan reports leadership roles with Sutro Biopharma; research funding to her institution from Janssen; consultant/advisory roles with Bristol Myers Squibb, GlaxoSmithKline and Janssen; speakers bureau roles with Amgen, Bristol Myers Squibb, GlaxoSmithKline and Takeda; and stock ownership in Bristol Myers Squibb.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.